#USA #Toronto #Alamar Biosciences #NULISA #tau proteins

Alamar Biosciences Showcases Innovative Data on Tau Proteins at AAIC 2025

Alamar Biosciences, a pioneering company in precision proteomics aimed at early disease detection, presented significant data on tau proteins derived from brain tissues at the Alzheimer’s Association International Conference (AAIC) 2025. This conference, hosted from July 27 to 31 in Toronto, Canada, provided a platform for over 30 scientific presentations and poster sessions highlighting advancements in neurodegenerative disease biomarkers.

The NULISA™ platform developed by Alamar is set to revolutionize biomarker detection by offering unmatched sensitivity, specificity, and multiplexed detection capabilities, crucial for diagnosing and monitoring neurodegenerative diseases. This year’s AAIC prominently featured clinical data collected via the NULISA platform, particularly in measuring phosphorylated tau proteins (pTau) in the brain. These findings are expected to significantly expedite the early diagnosis and therapeutic monitoring of Alzheimer’s disease (AD) and other related neurodegenerative conditions.

Key Highlights from the Presentation

During the presentation, Dr. Yuling Luo, founder and CEO of Alamar Biosciences, emphasized the importance of their findings, stating, “The presentation of pTau data obtained from brain tissues demonstrates not just the high sensitivity and specificity of NULISA, but also our commitment to advancing biomarkers for neurodegenerative diseases.” The product presentation took place on July 28 at 1:20 PM (Eastern Time) and featured expert contributions from Professor Jonathan Schott of University College London and Dr. Cheryl Wellington from the University of British Columbia.

1. Efficacy of pTau from Brain Samples

Alamar showcased results from a 1946 birth cohort, which involved new pTau isoforms identified using the NULISAseq™ CNS Disease Panel 120. These data indicated a remarkable ability of phosphorylated tau proteins from brain samples to predict Alzheimer’s disease years ahead of clinical diagnosis. This could lead to important changes in how we approach early detection and management of AD.

2. Correlation with Disease Progression

The data also illustrated a correlation between brain pTau levels and PET imaging of amyloid and tau proteins, presenting a clearer picture of disease progression and aiding in the understanding of Alzheimer's pathology.

3. Identification of Biomarkers

The analysis of a unique cohort of autopsy-verified patients using the NULISAseq™ CNS Disease Panel 120 revealed biomarkers that help identify neuropathologies and comorbidities associated with Alzheimer’s disease. These insights could facilitate more nuanced therapeutic approaches in treating patients with AD.

4. Preclinical Study Insights

Additionally, findings from the NULISAseq™ Mouse Panel 120 demonstrated its effectiveness in analyzing plasma and brain homogenate samples across various Alzheimer’s disease clinical models, which could encourage further preclinical research and validation.

The Significance of the AAIC Conference

The Alzheimer’s Association International Conference is a leading global forum where experts, researchers, clinicians, and stakeholders convene annually to share cutting-edge discoveries, foster collaboration, and accelerate the path toward effective diagnostic and therapeutic solutions for Alzheimer's disease and other dementia-related disorders. The full list of presentations and posters demonstrating NULISA data at AAIC can be found on the conference website.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private biomedical firm with the mission of enabling precision proteomics for early disease diagnosis. Their patented NULISA platform and ARGO HT System seamlessly integrate with the latest advancements in genomics, ensuring detection sensitivity at the attomolar level, surpassing the most sensitive protein detection technologies available today. For more information, visit alamarbio.com.